Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  epoetin alfa
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 57 for your search:
Start Over
Phase IV Study of Epoetin alfa in Women With Stage I, II, or III Breast Cancer and Chemotherapy-Related Anemia. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.
Phase: Phase IV
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UCLA-0011004, ORTHO-PR-00-27-012, ORTHO-PR-01-27-003, NCI-G01-2002, NCT00022386
A Study of the Safety and Effectiveness of Epoetin Alfa on Hemoglobin Levels and Blood Transfusions in Cancer Patients Receiving Chemotherapy
Phase: Phase IV
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR003541, NCT00216541
An Observational Study of Blood Management Techniques in Oncology Surgical Treatment
Phase: Phase IV
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR003460, EPOSUR4001, NCT00264095
Cost-effectiveness Study of Epoetin Alfa and Darbepoetin Alfa in Adult Patients With Cancer Who Have Anemia
Phase: Phase IV
Type: Health services research, Supportive care
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR002455, EPOCAN4015, NCT00264108
Survey on the Treatment of Anemia Using Recombinant Human Erythropoietin 2 (STAR-2)
Phase: Phase IV
Type: Natural history/Epidemiology, Supportive care
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR005596, EPOCAN4018, NCT00398749
LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk MDS
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLBH589BDE04, EudraCT 2009-010403-84, 2009-010403-84, NCT01034657
Phase III Randomized Study of Epoetin Alfa versus Placebo in Anemic Patients Receiving Chemotherapy for Stage IV Metastatic Breast Cancer (Summary Last Modified 02/1999)
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18-80
Sponsor: NCI
Protocol IDs: RPCI-DS-97-10, ORTHO-PR-96-27-004, NCI-G98-1394
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000066673, NCCTG-979253, NCI-P98-0133, 97-92-53, NCT00003600
Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer
Phase: Phase III
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: RTOG-9903, CDR0000067599, RTOG-DEV-1008, NCT00004917
Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia
Phase: Phase III
Type: Supportive care, Treatment
Status: Completed
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: GOG-0191, NCI-2012-02384, CAN-NCIC-CX4, CDR0000068641, U10CA027469, CX4, NCT00017004
Anemia in Patients With a Non-Myeloid Malignancy
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20010101, UCLA-0201098, NCI-G02-2112, AMGEN-200101101, NCT00046982, NCT00038064
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000288821, NCCTG-N02C2, NCT00058331
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000301881, ECOG-E1Z01, E1Z01, NCT00060398
Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000333213, P30CA016042, UCLA-0306021, AMGEN-20030125, NCT00070382
An Efficacy and Safety Study for Epoetin Alfa (PROCRIT) in Cancer Patients Not Receiving Chemotherapy or Radiation
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR003223, NCT00210587
Impact of Erythropoietin Administration During Definitive Cervix Cancer Radiotherapy on Treatment Outcome
Phase: Phase III
Type: Treatment
Status: Closed
Age: 19 to 80
Sponsor: Other
Protocol IDs: OEGRO54, NCT00348738
A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS
Phase: Phase III
Type: Supportive care
Status: Completed
Age: Not specified
Sponsor: Other
Protocol IDs: 2005-0890, NCT00656448
Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 60 and under
Sponsor: Other
Protocol IDs: MA21, CAN-NCIC-MA21, AMGEN-CAN-NCIC-MA21, NCCTG-CAN-NCIC-MA21, BMS-CAN-NCIC-MA21, JANSSEN-ORTHO-CAN-NCIC-MA21, PFIZER-CAN-NCIC-MA21, SWOG-CAN-NCIC-MA21, CDR0000068520, CALGB-CAN-NCIC-MA21, NCIC-MA21, NCT00014222
Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000069148, CCCWFU-62299, CCCWFU-BG01-193, NCI-P01-0200, NCT00028938
Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes
Phase: Phase III
Type: Supportive care, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000065907, E1996, U10CA021115, ECOG-1996, NCT00003138
An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR018367, EPOANE3021, 2010-022884-36, NCT01381809
Phase I/II Study of Escalating IL-6 with GM-CSF/EPO for Myelodysplastic Syndrome (Summary Last Modified 03/97)
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: RPMI-DS-9429, NCI-T94-0072D, T94-0072
Start Over